Impax Laboratories Inc. (IPXL) belonging to the Medical sector has surged 3.24% and closed its last trading session at $9.55.
The company reported its EPS on 03/01/2017. Currently, the stock has a 1 Year Price Target of $12.38.
The consensus recommendation, according to Zacks Investment research, is 2.8. The scale runs from 1 to 5 with 1 recommending Strong Buy and 5 recommending a Strong Sell.
The Stock had a 2.7 Consensus Analyst Recommendation 30 Days Ago, whereas 60 days ago and 90 days ago the analyst recommendations were 2.7 and 2.5 respectively.
Impax Laboratories Inc. on 03/01/2017 reported its EPS as $0.16 with the analysts projecting the EPS of the stock as $0.16. The company beat the analyst EPS Estimate with the difference of $0. This shows a surprise factor of 0%.
Many analysts have provided their estimated foresights on Impax Laboratories Inc. Earnings, with 10 analysts believing the company would generate an Average Estimate of $0.13.
Whereas they predicted High and Low Earnings Estimate as $0.19 and $0.07 respectively. While in the same Quarter Previous year, the Actual EPS was $0.43.
Analysts are also projecting an Average Revenue Estimate for Impax Laboratories Inc. as $191.31 Million in the Current Quarter. This estimate is provided by 9 analysts.
The High Revenue estimate is predicted as 201 Million, while the Low Revenue Estimate prediction stands at 179.8 Million. The company’s last year sales total was 225.51 Million.
For the Current Quarter, the growth estimate for Impax Laboratories Inc. is -69.8%, while for the Next Quarter the stock growth estimate is -23.8%.
In the past 5 years, the stock showed growth of -9.29% per annum. While for the next 5 years, the growth estimate is 14%.
The Company got Upgrade by Deutsche Bank on 8-Mar-17 from Hold to Buy.
Insider Trades for Impax Laboratories Inc. show that the latest trade was made on 1 Mar 2017 where Schlossberg (Mark A), the General Counsel completed a transaction type “Buy” in which 23272 shares were traded at a price of $0.
8 Insider Sales transactions were made totaling 118504 shares traded.
13 analysts projected Price Targets for Impax Laboratories Inc.. The analysts believe that the company stock price could grow as high as $20. The Low Price target projection by analysts is $7 and the Mean Price Target is $12.38.
Impax Laboratories Inc. (IPXL) has the market capitalization of $720.17 Million. The company rocked its 52-Week High of $37.2 on Apr 22, 2016 and touched its 52-Week Low of $7.75 on Mar 7, 2017.
The stock has Return on Assets (ROA) of -24.6 percent. Return on Equity (ROE) stands at -51.4% and Return on Investment (ROI) of -29.6 percent.
The stock is currently showing YTD performance of -27.92 Percent. The company has Beta Value of 1.28 and ATR value of 0.82. The Weekly and Monthly Volatility stands at 6.23% and 8.08%.